We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+30.61%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$82.6M
AUM Growth
+$6.27M
Cap. Flow
-$2.82M
Cap. Flow %
-3.41%
Top 10 Hldgs %
82.89%
Holding
26
New
8
Increased
1
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.99M
2
GERN icon
Geron
GERN
+$6.04M
3
VRDN icon
Viridian Therapeutics
VRDN
+$5.17M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$3.34M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$3.27M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$8.15M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$7.17M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.21M
4
MRSN
Mersana Therapeutics
MRSN
+$4.9M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
1
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.8M 13.04%
+105,558
New +$9.99M
VRNA
2
DELISTED
Verona Pharma
VRNA
$10.3M 12.49%
487,631
– –
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.48B
$10.3M 12.45%
266,961
– –
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$7.29M 8.83%
223,382
– –
GERN icon
5
Geron
GERN
$911M
$6.82M 8.25%
+2,123,162
New +$6.04M
MRUS
6
DELISTED
Merus
MRUS
$5.25M 6.35%
199,221
-76,749
-28% -$1.68M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.04B
$4.8M 5.81%
+201,752
New +$5.17M
MLTX icon
8
MoonLake Immunotherapeutics
MLTX
$1.62B
$4.66M 5.65%
91,413
+18,563
+25% +$499K
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.24M 5.14%
+390,418
New +$3.34M
BDTX icon
10
Black Diamond Therapeutics
BDTX
$102M
$4.04M 4.89%
+800,000
New +$1.63M
PRAX icon
11
Praxis Precision Medicines
PRAX
$8.63B
$3.68M 4.46%
+213,333
New +$3.27M
JSPR icon
12
Jasper Therapeutics
JSPR
$26.3M
$3.45M 4.18%
251,723
– –
CMPX icon
13
Compass Therapeutics
CMPX
$366M
$2.91M 3.52%
+914,630
New +$2.87M
MDVL
14
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$1.44M 1.75%
117,898
– –
MDXH icon
15
MDxHealth
MDXH
$21.3M
$1.19M 1.44%
349,552
-150,448
-30% -$550K
CNTX icon
16
Context Therapeutics
CNTX
$55.7M
$1.05M 1.27%
+653,396
New +$556K
RPID icon
17
Rapid Micro Biosystems
RPID
$104M
$403K 0.49%
403,284
-296,380
-42% -$300K
EPIX
18
DELISTED
ESSA Pharma
EPIX
– –
-236,583
Closed -$703K
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-29,614
Closed -$7.17M
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
– –
-47,651
Closed -$4.9M
SRPT icon
21
Sarepta Therapeutics
SRPT
$1.81B
– –
-20,830
Closed -$2.87M
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-249,126
Closed -$665K
KNTE
23
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-109,393
Closed -$684K
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-255,310
Closed -$6.21M
BLU
25
DELISTED
BELLUS Health Inc.
BLU
– –
-1,131,827
Closed -$8.15M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q2 2023 Portfolio in Review

As of Q2 2023, Ally Bridge Group held 26 positions worth $82.6M, up 8.2% from $76.3M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Ally Bridge Group withdrew a net $2.82M in Q2 2023, closing 9 positions and reducing 3 holdings. Its most notable exit was BELLUS Health Inc., an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Ally Bridge Group opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $10.8M.

  • Ally Bridge Group's largest Q2 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 105,558 shares worth $10.8M.
  • Ally Bridge Group added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $499K increase.
  • Ally Bridge Group's biggest Q2 2023 reduction was Merus, cutting an estimated $1.68M.
  • Ally Bridge Group fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $8.15M.
  • Ally Bridge Group's ten largest holdings make up 83% of its $82.6M portfolio in Q2 2023.
  • Ally Bridge Group opened 8 new positions and closed 9 in Q2 2023.
  • Ally Bridge Group's portfolio value rose 8.2% quarter-over-quarter to $82.6M.

Based on Ally Bridge Group's 13F filing for Q2 2023, filed 14 Aug 2023.